Epithalon

Mechanism

In cell culture, epithalon has been reported to induce expression of the telomerase catalytic subunit (hTERT) and to elongate telomeres in telomerase-negative human fetal fibroblasts (Khavinson et al., 2003), with a 2025 independent cell-line study describing telomere lengthening via telomerase upregulation and/or alternative lengthening of telomeres (ALT). Proposed additional actions include modulation of pineal melatonin secretion and gene expression. These mechanisms derive largely from in-vitro and preclinical work and remain incompletely verified in humans.

Regulatory Status by Region

• United States (FDA)Not FDA-approved for any indication. Historically placed on the FDA 503A 'Category 2' bulk drug substances list (substances with significant safety concerns) restricting pharmacy compounding; subject of ongoing FDA compounding review in 2026.
• Australia (TGA)Not approved by the TGA and not entered on the Australian Register of Therapeutic Goods (ARTG); no registered therapeutic product.
• European Union (EMA)No EMA marketing authorisation; not an approved medicine in the EU.
• WADANot listed by name on the Prohibited List, but unapproved peptides of this type are generally captured by the S0 'Non-Approved Substances' category (any pharmacological substance with no current approval by a governmental health authority for human therapeutic use), which is prohibited at all times. Athletes should treat it as prohibited.

Key Studies

• Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells (Khavinson VK, Bondarev IE, Butyugov AA. Bull Exp Biol Med. 2003;135(6):590-592.)
• Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity (Scientific Reports (2025), PMC12411320.)
• Overview of Epitalon - Highly Bioactive Pineal Tetrapeptide with Promising Properties (review) (PMC11943447.)